Abbott's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose ...

Argus analyst David Toung raised the firm’s price target on Abbott (ABT) to $150 from $145 and keeps a Buy rating on the shares. Abbott’s ...

Abbott Laboratories is a well-diversified health care company, with four distinct units: medical devices, diagnostics, nutrition and ...

Abbott reported Q4 sales of $11 billion missing the consensus; adjusted EPS was $1.34, matching analyst estimates Medical Device sales surged 13.7% to $5.05 billion, with FreeStyle Libre and AVEIR ...

Healthcare costs in the U.S. continue to rise, making it difficult for millions of people to afford essential medical ...

Detailed price information for Abbott Laboratories (ABT-N) from The Globe and Mail including charting and trades.

Financial analysis of Abbott Laboratories Q4 2024 results and 2025 outlook, with a 'Buy' rating due to revenue growth and EPS ...

Beta Bionics has announced the pricing of its upsized initial public offering of 12 million shares of common stock at a price to the public of $17 per share.

DexCom, Inc.'s growth is impressive but limited by its niche market, with my projected ceiling ... products – Abbott Laboratories' (ABT) Freestyle Libre, and Medtronics (MDT) unbranded devices ...

Beta Bionics has begun life as a public company with a $204m initial public offering (IPO), significantly higher than its ...

Based on its FreeStyle Libre ... price dipped in premarket trading, with first-quarter guidance falling below Wall Street estimates, but recovered and closed the gap within an hour of the market ...